Human leukocyte antigen-E (HLA-E) has been extensively investigated in various human cancers including glioma. However, the clinical significance of HLA-E expression in glioma patients has not been elucidated. The current study aimed to investigate the association of HLA-E expression with clinicopathological features and survival in patients with diffuse glioma. A total of 261 glioma patients were enrolled, subsequently, mRNA microarray analysis was conducted to identify the relationship of HLA-E with clinicopathological features and patient survival. HLA-E was significantly overexpressed in high-grade gliomas compared to low-grade gliomas (LGGs). Moreover, HLA-E expression was significantly higher in diffuse astrocytomas than oligodendrogliomas (p = 0.032, t-test). Kaplan-Meier analysis showed that progression-free survival (PFS) and overall survival (OS) were significantly better in LGG patients with low HLA-E expression (p = 0.018 for PFS and p = 0.020 for OS, Log-rank test). Furthermore, HLA-E expression was identified to be an independent prognostic factor by Cox analysis (p = 0.020 for PFS and p = 0.024 for OS). This is the first study which identified the clinical significance of HLA-E in diffuse glioma. HLA-E expression was correlated with more aggressive tumor grade and histological type and was identified as an independent prognostic biomarker in LGG patients.

中文翻译：

---

弥漫性胶质瘤中 HLA-E 的表达：与临床病理特征和患者生存的关系。


人类白细胞抗原-E (HLA-E) 已在包括神经胶质瘤在内的各种人类癌症中得到广泛研究。然而，胶质瘤患者中HLA-E表达的临床意义尚未阐明。本研究旨在探讨 HLA-E 表达与弥漫性胶质瘤患者临床病理特征和生存的关系。总共招募了 261 名胶质瘤患者，随后进行 mRNA 微阵列分析，以确定 HLA-E 与临床病理特征和患者生存的关系。与低级别神经胶质瘤 (LGG) 相比，HLA-E 在高级神经胶质瘤中显着过度表达。此外，弥漫性星形细胞瘤中的 HLA-E 表达显着高于少突胶质细胞瘤（p = 0.032，t 检验）。 Kaplan-Meier 分析显示，HLA-E 表达低的 LGG 患者的无进展生存期 (PFS) 和总生存期 (OS) 明显更好（PFS 为 p = 0.018，OS 为 p = 0.020，Log-rank 检验）。此外，通过 Cox 分析，HLA-E 表达被确定为独立的预后因素（PFS 的 p = 0.020，OS 的 p = 0.024）。这是第一项确定 HLA-E 在弥漫性神经胶质瘤中的临床意义的研究。 HLA-E 表达与更具侵袭性的肿瘤分级和组织学类型相关，并被确定为 LGG 患者的独立预后生物标志物。